Navigation Links
Inovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011
Date:5/17/2011

herapies and the promotion of professional and public education in the field.

About Inovio Pharmaceuticals, Inc. Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. Its SynCon™ vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio's proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio clinical programs include three Phase II studies for vaccines treating cervical dysplasia/cancer, hepatitis C virus, and leukemia. Other clinical programs target influenza (preventive) and HIV (preventive and therapeutic). Inovio partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
2. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
3. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
4. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
5. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
6. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
7. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
8. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
9. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
10. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
11. Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 BioDelivery Sciences International, Inc. ... Board of Directors has appointed Charles J. (Chuck) ... as members of the Board.  Mr. ... experience in marketing, sales and other commercial functions.  He ... Inc., a development stage company that was recently acquired ...
(Date:7/22/2014)... , July 22, 2014  NeuroSigma, Inc. (NeuroSigma), a ... on commercialization of its non-invasive Monarch ™ ... neuropsychiatric disorders, today announced that enrollment has begun in ... stimulation (eTNS) as adjunctive therapy for the treatment of ... conducted at the Olive View-UCLA Medical Center in ...
(Date:7/21/2014)... ANGELES , July 21, 2014 /PRNewswire-iReach/ -- Nitrosolution.com, ... oxide supplements , will celebrate its first anniversary in ... that is designed to enhance the body,s ability to ... formula that is made up of a variety of ... said have been found to increase nitric oxide ...
Breaking Medicine Technology:BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 2BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 3BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 4BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 5BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 6BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 7Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5Up and Coming Nitric Oxide Supplements Company Nitrosolution.com Celebrates its One Year Anniversary 2
... -First Combination Study of a MET and EGFR Inhibitor-, ... (Nasdaq: EXEL ) today announced that it has ... non-small cell lung cancer (NSCLC) who have had,progressive disease ... a small molecule that simultaneously inhibits the MET, RET ...
... ASHBURN, Va., Jan. 4 Innocoll, Inc., ... first of a series of,planned phase 2 ... subsidiary,Innocoll Technologies Ltd, to investigate CollaRx(R) BUPIVACAINE ... has commenced dosing., Innocoll,s BUPIVACAINE SURGICAL ...
Cached Medicine Technology:Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 2Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 3Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 4Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 2Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 4
(Date:7/22/2014)... July 22, 2014 According to a ... care, Automobile, Aerospace & Defense, Marine and Mining) & ... East, and Rest of the world) - Forecast Analysis ... expected to grow at a CAGR 8.00% to reach ... is estimated to grow at a CAGR of 6.00% ...
(Date:7/22/2014)... Carlsbad, CA (PRWEB) July 22, 2014 ... 0% financing for 24 months on all models during ... 18th-28th. , Please visit http://www.d1spas.com/financing for ... leader in hydrotherapy, Dimension One Spas offers a wide ... your fingertips including lights, fountains, waterfalls, music, customizable massage, ...
(Date:7/22/2014)... -- People who suffer long-term sleep problems after a ... pressure, a new study suggests. Previous research has ... death, but few studies have examined the reasons for ... causes, according to the University of Arizona investigators. ... or divorced for about 16 weeks. They reported on ...
(Date:7/22/2014)... a five-year, $3 million grant to study how ... maltreatment during childhood leave molecular marks in DNA ... The Center for Biomarker Research and Personalized Medicine ... with Duke University School of Medicine, will conduct ... National Institutes of Health, National Institute of Mental ...
(Date:7/22/2014)... Belmont, CA (PRWEB) July 22, 2014 ... and publisher for women, this year celebrates its tenth ... Silicon Valley. Thousands of attendees, including community leaders from ... sponsoring brands representing every consumer vertical, will converge in ... cutting edge conversation, and a “selfiebration” of social technology. ...
Breaking Medicine News(10 mins):Health News:Global Actuators Market Estimated to Reach $59.32 Billion by 2019 – New Report by MarketsandMarkets 2Health News:Global Actuators Market Estimated to Reach $59.32 Billion by 2019 – New Report by MarketsandMarkets 3Health News:Global Actuators Market Estimated to Reach $59.32 Billion by 2019 – New Report by MarketsandMarkets 4Health News:Sleepless Nights After Divorce May Be Tied to Blood Pressure Rise 2Health News:VCU receives grant to study molecular marks left by childhood adverse experiences 2Health News:BlogHer, Inc. Comes Home to Silicon Valley for 10th Anniversary: World’s Largest Event for Bloggers and Social Media Influencers 2Health News:BlogHer, Inc. Comes Home to Silicon Valley for 10th Anniversary: World’s Largest Event for Bloggers and Social Media Influencers 3Health News:BlogHer, Inc. Comes Home to Silicon Valley for 10th Anniversary: World’s Largest Event for Bloggers and Social Media Influencers 4
... 8 A woman in the United,States is ... finding,breast cancer at an early stage greatly improves ... most important woman in all our lives, our,mothers, ... celebrating,Mother,s Day by involving the culinary community and ...
... Hospital buildings can heal,according to the first ... the,physical environment on child patients in health care ... through the,Physical Environment is produced by the National ... partnership with the Center,for Health Design. Findings from ...
... 7 As the result of San ... chapters, the,North-American Interfraternity Conference supports the decisions ... officials to hold those,responsible parties accountable for ... will continue to collaborate with our member ...
... May 7 The top of the Empire State ... Picchu. James Chippendale is a,leukemia survivor and co-founder of ... concerts in high locations to,raise funds for cancer centers ... with a very aggressive form of,leukemia. His doctors gave ...
... 7 Oracle Healthcare,Acquisition Corp. (the "Company") (OTC ... approve the dissolution of the Company and,its proposed ... proxy,statement dated April 16, 2008, at the special ... As previously announced, the Company has set May ...
... COLUMBIA, Mo. Telehealth, using telecommunication technology to ... improve the delivery and availability of health care ... found that patients who received a telehealth intervention ... rates when compared to patients who received traditional ...
Cached Medicine News:Health News:Celebrity Chefs and America's Restaurants Cook for the Cure This Mother's Day 2Health News:Celebrity Chefs and America's Restaurants Cook for the Cure This Mother's Day 3Health News:Hospital Buildings Can Heal According to First Comprehensive Report on Impact of Physical Environment on Child Patients 2Health News:Hospital Buildings Can Heal According to First Comprehensive Report on Impact of Physical Environment on Child Patients 3Health News:Hospital Buildings Can Heal According to First Comprehensive Report on Impact of Physical Environment on Child Patients 4Health News:James Chippendale Climbs the Mountain of Life 2Health News:Oracle Healthcare Acquisition Corp. Announces Stockholder Approval of Proposed Dissolution and Plan of Liquidation 2Health News:Patients with chronic illness benefit from telehealth intervention 2